LDS/Medical Tests/DNA Methylation Gene Panel for Barrett's Esophagus (EndoSign®)

DNA Methylation Gene Panel for Barrett's Esophagus (EndoSign®)

Barrett’s esophagus is a premalignant condition in which the normal squamous epithelium of the esophagus is replaced by metaplastic intestinal-type epithelium, typically as a consequence of chronic gastroesophageal reflux disease (GERD). Symptoms include persistent heartburn, regurgitation, dysphagia, chronic cough, and sore throat. Barrett’s esophagus is clinically significant because it increases the risk of developing esophageal adenocarcinoma (EAC), a highly lethal cancer with a 5-year survival rate of less than 20%. Early identification of patients at highest risk is critical, as prognosis improves markedly with early detection and intervention.

The EndoSign® DNA Methylation Gene Panel is a liquid biopsy assay that uses next-generation sequencing (NGS) to analyze methylation patterns in esophageal epithelial cells. This assay detects differentially methylated genomic regions associated with progression from Barrett’s esophagus to EAC, enabling more precise risk stratification. The test uses a non-endoscopic capsule sponge device to collect pan-esophageal cell samples, providing a minimally invasive alternative to standard endoscopy.

Clinical studies have shown that DNA methylation markers can accurately distinguish high-risk patients with Barrett’s esophagus, improving surveillance strategies and enabling early, potentially curative interventions.

  • Identifies patients with Barrett’s esophagus at higher risk for progression to esophageal adenocarcinoma
  • Provides a minimally invasive alternative to endoscopy for risk assessment
  • May reduce unnecessary endoscopies in low-risk patients

Positive: Indicates increased likelihood of progression to esophageal adenocarcinoma. Patients may require intensified surveillance, confirmatory endoscopy, and potential early therapeutic intervention.

Negative: Suggests lower risk of progression. Barrett’s esophagus is less likely to advance to malignancy, though routine surveillance remains recommended.

Negative

Liquid biopsy and Next-generation sequencing (NGS) with methylation analysis of ≥89 genomic regions.

The Endosign Barrett’s Esophagus test uses a non-endoscopic capsule sponge procedure to collect pan-esophageal cell sample for analysis

Stability

Per manufacturer’s instructions (ambient transport recommended).

Biopsy, esophagus, EsoGuard methylation Assay for Barrett’s esophagus, comprehensive metabolic panel.
5 to 10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login